Microbiota-based therapies for chronic kidney disease

Dessy Natasha Ade Putri (Medical Science Study Program, Medical Faculty of Udayana University)
Chika Christianne Moreen Nababan (Medical Science Study Program, Medical Faculty of Udayana University)

ISM (Intisari Sains Medis) : Jurnal Kedokteran
Vol. 10 No. 1 (2019): (Available online 1 April 2019)

Background: Increasing prevalence of chronic kidney disease (CKD) worldwide has been concerned as a global public health issue because of the burden of adverse outcomes, including mortality. Gut microbiota can be used as a potential therapeutic target to slow the progression of CKD.Aim: This literature review aims to provide an in-depth review about the potency of microbiota-based therapy for CKD.Method: from 58 journals reviewed, 51 were found suitable as references for this paper. The keywords used are “gut microbiota,” “chronic kidney disease”, “prebiotic”, “probiotic” and “fecal microbiota transplantation” on selected search engines.Result: In general, it has shown that microbiota-based therapies do have potential therapeutic effect as it can improve inflammatory response, uremic toxin, insulin resistance and cardiovascular risk.Conclusion: Prebiotic, probiotic, fecal microbiota transplantation and novel therapies have shown beneficial effects in treating patients with CKD.